The one after almost a year, it has received approval from the U.S. Food and Drug Administration (FDA), beginning Tuesday, will be the new prescription weight loss drug for some patients.
FDA approves Belviq, the oral drug in June 2012. Availability delay, DEA, since it is necessary to confirm the drug is part.
People have been prescribed by a doctor to a weight of at least one state as a BMI of 27 or body index of more than 30 patients with type 2 diabetes and high blood pressure that way.
http://slimmingcapsule.soulcast.com
Belviq, FDA announced the approval, it said in its statement last year, the goal is "in addition to exercise and a low calorie diet."
The lorcaserin hydrochloride or Belviq, 5 by the activation of the brain - serotonin receptor, can help people to eat less and be full after eating a small amount of food according to the FDA.
To be admitted, about the same time, Belviq is on the market in September other than weight loss drug Qsymia.
Weight loss and the two drugs These are modest. Going clinical studies at 227-204 pounds Qsymia average patient; Belviq decreased average weight 207-220.
According to the FDA, without loss of at least 5% of body weight Belviq, In the test, 47% of patients with type 2 diabetes. In contrast, 23% of placebo-treated patients had lost at least 5% of their weight. In type 2 diabetes, the patient Belviq 38% to 16% compared to placebo, and lost at least 5% of body weight.
http://www.iseekblog.com/entry.php?w=slimmingcapsule&e_id=1859471
No comments:
Post a Comment